169 related articles for article (PubMed ID: 32586246)
1. Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future Directions.
Klingler M; Hörmann AA; Guggenberg EV
Curr Med Chem; 2020; 27(41):7112-7132. PubMed ID: 32586246
[TBL] [Abstract][Full Text] [Related]
2. Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.
Zavvar TS; Hörmann AA; Klingler M; Summer D; Rangger C; Desrues L; Castel H; Gandolfo P; von Guggenberg E
Pharmaceuticals (Basel); 2023 Feb; 16(2):. PubMed ID: 37052226
[TBL] [Abstract][Full Text] [Related]
3. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy.
Mather SJ; McKenzie AJ; Sosabowski JK; Morris TM; Ellison D; Watson SA
J Nucl Med; 2007 Apr; 48(4):615-22. PubMed ID: 17401100
[TBL] [Abstract][Full Text] [Related]
4. 1,5-Disubstituted 1,2,3-Triazoles as Amide Bond Isosteres Yield Novel Tumor-Targeting Minigastrin Analogs.
Grob NM; Schibli R; Béhé M; Valverde IE; Mindt TL
ACS Med Chem Lett; 2021 Apr; 12(4):585-592. PubMed ID: 33859799
[TBL] [Abstract][Full Text] [Related]
5. Acidity-Triggered "Sticky Spotlight": CCK2R-Targeted TME-Sensitive NIR Fluorescent Probes for Tumor Imaging
Sun R; Wang Y; Shi W; Zhang H; Liu J; He W
Bioconjug Chem; 2024 Apr; 35(4):528-539. PubMed ID: 38514970
[TBL] [Abstract][Full Text] [Related]
6. Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms.
Fani M; Peitl PK; Velikyan I
Pharmaceuticals (Basel); 2017 Mar; 10(1):. PubMed ID: 28295000
[No Abstract] [Full Text] [Related]
7. Heterodimerization of cholecystokinin 1 and cholecystokinin 2 receptors in gallbladder cancer: a new mechanism for carcinogenesis.
Nigam J; Kazmi HR; Khare L; Srivastava M; Chandra A
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7069-7078. PubMed ID: 36871090
[TBL] [Abstract][Full Text] [Related]
8. Discovery of the cyclotide caripe 11 as a ligand of the cholecystokinin-2 receptor.
Taghizadeh MS; Retzl B; Muratspahić E; Trenk C; Casanova E; Moghadam A; Afsharifar A; Niazi A; Gruber CW
Sci Rep; 2022 Jun; 12(1):9215. PubMed ID: 35654807
[TBL] [Abstract][Full Text] [Related]
9. Development of a time-resolved fluorescence probe for evaluation of competitive binding to the cholecystokinin 2 receptor.
Elshan NG; Jayasundera T; Weber CS; Lynch RM; Mash EA
Bioorg Med Chem; 2015 Apr; 23(8):1841-8. PubMed ID: 25769518
[TBL] [Abstract][Full Text] [Related]
10. Radiolabeled peptides and their expanding role in clinical imaging and targeted cancer therapy.
Aloj L; Mansi R; De Luca S; Accardo A; Tesauro D; Morelli G
J Pept Sci; 2024 May; ():e3607. PubMed ID: 38710638
[TBL] [Abstract][Full Text] [Related]
11. Computational studies and synthesis of
Sugiharti RJ; Maharani R; Kurniawan F; Kartasasmita RE; Tjahjono DH
RSC Adv; 2024 Apr; 14(16):10962-10968. PubMed ID: 38577429
[TBL] [Abstract][Full Text] [Related]
12. Initial In Vitro and In Vivo Evaluation of a Novel CCK2R Targeting Peptide Analog Labeled with Lutetium-177.
Hörmann AA; Klingler M; Rezaeianpour M; Hörmann N; Gust R; Shahhosseini S; Guggenberg EV
Molecules; 2020 Oct; 25(19):. PubMed ID: 33049999
[TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin receptors.
Wank SA
Am J Physiol; 1995 Nov; 269(5 Pt 1):G628-46. PubMed ID: 7491953
[TBL] [Abstract][Full Text] [Related]
14. CCK Receptor Inhibition Reduces Pancreatic Tumor Fibrosis and Promotes Nanoparticle Delivery.
Abraham T; Armold M; McGovern C; Harms JF; Darok MC; Gigliotti C; Adair B; Gray JL; Kelly DF; Adair JH; Matters GL
Biomedicines; 2024 May; 12(5):. PubMed ID: 38790986
[TBL] [Abstract][Full Text] [Related]
15. Advances in Radioligand Theranostics in Oncology.
Lawal IO; Abubakar SO; Ndlovu H; Mokoala KMG; More SS; Sathekge MM
Mol Diagn Ther; 2024 May; 28(3):265-289. PubMed ID: 38555542
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution Assessment of a Novel
Pavone AM; Benfante V; Giaccone P; Stefano A; Torrisi F; Russo V; Serafini D; Richiusa S; Pometti M; Scopelliti F; Ippolito M; Giannone AG; Cabibi D; Asti M; Vettorato E; Morselli L; Merone M; Lunardon M; Andrighetto A; Tuttolomondo A; Cammarata FP; Verona M; Marzaro G; Mastrotto F; Parenti R; Russo G; Comelli A
Life (Basel); 2024 Mar; 14(3):. PubMed ID: 38541733
[TBL] [Abstract][Full Text] [Related]
17. Precision peptide theranostics: developing
Rahimi MN; Corlett A; Van Zuylekom J; Sani MA; Blyth B; Thompson P; Roselt PD; Haskali MB
Theranostics; 2024; 14(5):1815-1828. PubMed ID: 38505611
[TBL] [Abstract][Full Text] [Related]
18. Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic.
Rizvi SFA; Zhang L; Zhang H; Fang Q
ACS Pharmacol Transl Sci; 2024 Feb; 7(2):309-334. PubMed ID: 38357281
[TBL] [Abstract][Full Text] [Related]
19. Detecting radio- and chemoresistant cells in 3D cancer co-cultures using chromatin biomarkers.
Pekeč T; Venkatachalapathy S; Shim AR; Paysan D; Grzmil M; Schibli R; Béhé M; Shivashankar GV
Sci Rep; 2023 Nov; 13(1):20662. PubMed ID: 38001169
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
